Q-omics provides the consensus-scored C16orf74 profile across patient tissues and cancer cell-line models. C16orf74 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C16orf74 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, C16orf74 RNA expression shows 15,266 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ACC, HNSC, and ESCA as cancer lineages where C16orf74 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C16orf74 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C16orf74 survival associations across molecular data types. C16orf74 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C16orf74 RNA expression–survival associations across cancer types. High C16orf74 expression shows unfavorable associations in ACC, UCEC, COAD, PAAD, SKCM and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C16orf74 RNA expression.
This table summarizes C16orf74 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for C16orf74. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C16orf74 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LUSC, KIRP and LUAD. The HNSC box plot shows higher C16orf74 RNA expression in tumor versus normal tissue (log2 FC = +2.676, t-test p < 0.001).
This table shows molecular features associated with C16orf74 in patient tissues and cancer cell lines. In patient samples, C16orf74 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, C16orf74 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
